San Jose-based biotechnology company, Anixa Biosciences, Inc., has made significant strides in the development of therapies and vaccines to address critical unmet needs in oncology and infectious diseases. Among its most promising targets are therapies for ovarian cancer and anti-viral drug candidates for COVID-19. Anixa's chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell technology, has shown great promise in treating ovarian cancer. Meanwhile, its anti-viral drug candidates work by inhibiting certain protein functions of the virus. In terms of vaccines, Anixa is working on a vaccine against triple negative breast cancer and a preventative vaccine targeting ovarian cancer. By harnessing the power of immuno-therapy drugs, Anixa is also working on new treatments for various forms of cancer. The company, which was formerly known as ITUS Corporation, changed its name to Anixa Biosciences, Inc. in October 2018. With deep roots since its incorporation in 1982, Anixa Biosciences, Inc. is poised to lead the way in biotech innovation.
Anixa Biosciences's ticker is ANIX
The company's shares trade on the NASDAQ stock exchange
They are based in San Jose, California
There are 1-10 employees working at Anixa Biosciences
It is anixa.com/about/overview
Anixa Biosciences is in the Healthcare sector
Anixa Biosciences is in the Biotechnology industry
The following five companies are Anixa Biosciences's industry peers: